MAPT and Alzheimer disease: Geldanamycin (GM) (Fig. (2)), an Hsp90 inhibitor [28], induced a dose-dependent increase of Hsp70 in an AD cell model, as well as in rat primary cortical neurons [19] and reduced the amount of insoluble tau and the basal levels of okadaic-acid induced tau phosphorylation [19].